Business Context and Reporting Period
Company: Arvinas, Inc. (ARVN)
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2026
Event: Announcement of positive Phase 1 clinical trial data for ARV-102, an investigational PROTAC targeting LRRK2 for Parkinson's disease, presented at the AD/PD 2026 conference in Copenhagen.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding clinical trial results and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The report details significant clinical progress for ARV-102 in a single-center, randomized, double-blind, placebo-controlled, multiple-dose (MD) cohort:
- Efficacy: Achieved greater than 50% LRRK2 degradation in cerebrospinal fluid (CSF) at all tested doses (20 mg, 40 mg, 80 mg) by day 14, maintained through day 28.
- Brain Penetration: CSF levels increased in a dose-dependent manner, confirming blood-brain barrier crossing.
- Safety: Doses were well tolerated. All treatment-emergent adverse events were mild. No serious adverse events, discontinuations, or deaths were reported.
- Pharmacokinetics: Mean terminal plasma half-life was 68 hours. Peripheral biomarkers consistent with healthy volunteer data.
- Biomarkers: Reduction observed in endolysosomal and neuroinflammatory pathway proteins (e.g., CD68, GPNMB).
Guidance, Outlook, and Risks
Management Outlook:
- Plans to continue investigating ARV-102 in neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction.
- Intends to initiate a Phase 1b clinical trial in progressive supranuclear palsy in Q2 2026, pending regulatory feedback.
- Potential to initiate a registrational trial in late 2026 while evaluating development options for Parkinson's disease.
- The filing contains forward-looking statements subject to substantial risks and uncertainties.
- Future plans (Phase 1b and registrational trials) are contingent on regulatory feedback.
- Actual results may differ materially from expectations due to factors discussed in the company's Risk Factors sections.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical data not summarized in the 8-K.
- Confirm the specific regulatory feedback timeline required before initiating the Q2 2026 Phase 1b trial.
- Review the company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not provide financial data.
- Monitor subsequent filings for updates on the decision to proceed with a registrational trial in late 2026.